Praluent(alirocumab)
Praluent (alirocumab) is an antibody pharmaceutical. Alirocumab was first approved as Praluent on 2015-07-24. It is used to treat atherosclerosis and hypercholesterolemia in the USA. It has been approved in Europe to treat dyslipidemias. The pharmaceutical is active against proprotein convertase subtilisin/kexin type 9.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Praluent (discontinued: Praluent)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Alirocumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Praluent | alirocumab | Regeneron Pharmaceuticals | N-125559 RX | 2015-07-24 | 2 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| praluent | Biologic Licensing Application | 2024-09-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hypercholesterolemia | HP_0003124 | D006937 | — |
| atherosclerosis | EFO_0003914 | D050197 | I25.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
alirocumab, Praluent, Regeneron Pharmaceuticals, Inc. | |||
| 2028-04-01 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | — | 10 | 9 | 26 | 6 | 6 | 57 |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | — | 3 | 8 | 2 | 1 | 14 |
| Dyslipidemias | D050171 | HP_0003119 | — | — | 2 | 1 | 4 | 6 | 13 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 2 | 1 | 2 | 4 | 4 | 13 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | 3 | 2 | 3 | 8 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | 1 | 1 | 5 | 8 |
| Hyperlipidemias | D006949 | HP_0003077 | E78.5 | — | 1 | 1 | 3 | 1 | 6 |
| Coronary artery disease | D003324 | — | I25.1 | 1 | — | — | 3 | 2 | 6 |
| Atherosclerotic plaque | D058226 | HP_0031678 | I70 | — | — | 2 | 3 | 1 | 6 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | 1 | — | — | 3 | 1 | 5 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | 1 | 1 | 1 | — | — | 3 |
| Pathologic constriction | D003251 | — | — | — | — | 2 | — | 1 | 3 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 1 | 1 | 1 | — | — | 2 |
| Homozygous familial hypercholesterolemia | D000090542 | — | — | — | — | 2 | — | — | 2 |
| Septic shock | D012772 | — | A48.3 | — | 1 | 1 | — | — | 1 |
| Shock | D012769 | — | R57.1 | — | 1 | 1 | — | — | 1 |
| Peritoneal dialysis | D010530 | — | — | — | — | 1 | — | — | 1 |
| Carotid artery diseases | D002340 | EFO_0003781 | — | — | — | 1 | — | — | 1 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | — | 1 | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | — | 1 |
Show 7 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| St elevation myocardial infarction | D000072657 | — | — | — | 1 | — | — | 1 | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | — | — | — | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 2 | — | — | — | 2 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | — | 1 | — | — | — | 1 |
| Nephrosis | D009401 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Pharmacological phenomena | D000069437 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Binge drinking | D063425 | — | — | 1 | — | — | — | — | 1 |
| Alcoholic intoxication | D000435 | — | — | 1 | — | — | — | — | 1 |
| Drinking behavior | D004327 | EFO_0004315 | — | 1 | — | — | — | — | 1 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Genetic testing | D005820 | — | — | — | — | — | — | 1 | 1 |
| Hyperlipoproteinemia type iii | D006952 | — | — | — | — | — | — | 1 | 1 |
| Arthrogryposis | D001176 | EFO_0003857 | — | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | — | 1 | 1 |
| Treatment adherence and compliance | D000074822 | — | — | — | — | — | — | 1 | 1 |
| Patient compliance | D010349 | — | — | — | — | — | — | 1 | 1 |
| Motivational interviewing | D062405 | — | — | — | — | — | — | 1 | 1 |
| Compliance | D003187 | — | — | — | — | — | — | 1 | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | — | 1 | 1 |
| Genetic polymorphism | D011110 | — | — | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Alirocumab |
| INN | alirocumab |
| Description | Alirocumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109540 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB09302 |
| UNII ID | PP0SHH6V16 (ChemIDplus, GSRS) |
Target
Agency Approved
PCSK9
PCSK9
Organism
Homo sapiens
Gene name
PCSK9
Gene synonyms
NARC1
NCBI Gene ID
Protein name
proprotein convertase subtilisin/kexin type 9
Protein synonyms
convertase subtilisin/kexin type 9 preproprotein, NARC-1, neural apoptosis regulated convertase 1, Neural apoptosis-regulated convertase 1, PC9, Proprotein convertase 9, Subtilisin/kexin-like protease PC9
Uniprot ID
Mouse ortholog
Pcsk9 (100102)
proprotein convertase subtilisin/kexin type 9 (Q8CFT6)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Praluent – Regeneron Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Praluent – Sanofi
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,625 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
20,134 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use